SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To assess the sexual function improvement from baseline to the end of treatment (Week 24
or premature withdrawal (PW)) with XATRAL 10mg OD.
Secondary Objective:
- To evaluate the association between Lower Urinary Tract Symptoms (LUTS) severity and
sexual disorders,
- To compare the improvement in sexual function, urinary symptoms and Quality of Life
among the different regions,
- To correlate MSHQ (Male Sexual Health Questionnaire) and IIEF-5 (the 5-Item version of
the International Index of Erectile Function),
- To assess the onset of action of XATRAL 10mg OD,
- To assess the peak flow rate improvement (Qmax),
- To assess the safety and the tolerability of XATRAL 10mg OD.